Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guangxitoxin-1E (GxTx-1E) is a 36-amino acid peptidyl neurotoxin originally isolated from the venom of the tarantula *Plesiophrictus guangxiensis* (also known as *Chilobrachys guangxiensis*). It acts as a potent and selective gating modifier of voltage-gated potassium channels, primarily targeting Kv2.1 (KCNB1) and Kv2.2 (KCNB2) with nanomolar affinity, and to a lesser extent Kv4.3 (KCND3). By binding to the voltage-sensing domains of these channels, guangxitoxin-1E shifts their activation to more depolarized potentials, effectively inhibiting potassium efflux. In pancreatic beta cells, this blockade broadens action potentials, enhances glucose-stimulated calcium oscillations, and increases insulin secretion. Guangxitoxin-1E is widely utilized as a research-use-only (RUO) laboratory tool to investigate the physiological roles of Kv2 channels in neuronal excitability and endocrine function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guangxitoxin-1E.